On May 6, 2024, Cellectis S.A., closed the transaction. As the result of the transaction, AstraZeneca PLC, now owns approximately 44% of the share capital and 30% of the voting rights of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,190 GBX | +1.35% | -0.86% | +15.00% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,190 GBX | +1.35% | -0.86% | 240B | ||
2.41 EUR | -1.63% | -3.98% | 261M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.00% | 240B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Cellectis S.A. announced that it has received $140 million in funding from AstraZeneca PLC